Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LITE: Low Dose IL-2 in Liver Transplantation
NCT02949492Phase 4Terminated
- Sponsor
- King's College London
- Start
- Dec 2017
- Primary completion
- Jan 2019
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of aldesleukin in Liver transplant rejection, sponsored by King's College London. Primary endpoint: Discontinuation of immunosuppression drugs. Started Dec 2017; status: terminated.
02
Drugs
aldesleukin
03
Conditions
Liver transplant rejection
Beyond the preview
Go deeper on NCT02949492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02949492.